Check-Cap Doubles; FDA OKs Request to Study Polyp-Detection Test
Check-Cap stock jumped after the FDA cleared the company to conduct a study of a test to detect polyps that could become colorectal cancer.
Author:
Check-Cap (
CHEK) - Get Report nearly tripled on Monday after the medical-diagnostics company said the U.S. Food and Drug Administration approved its investigational device exemption application, clearing the way for a study of its C-Scan polyp-detection test.
Shares of the Isfiya, Israel, company at last check were at $3.17, compared with their Friday close at $1.53. They've traded on Monday at as much as $4.49. In November they were trading at a 52-week low 24 cents.